Amgen, others may benefit from reform-Barron's

NEW YORK, Jan 3 (Reuters) - The healthcare reform bill currently winding its way through the U.S. Congress may make the shares of some health and drug companies more attractive, Barron’s wrote in its Jan. 4 edition.

Stocks in the healthcare sector are trading at discounts even though the final version of the Obama administration’s proposed reform represents less of an important change than expected, the financial weekly wrote, citing Rockefeller & Co analyst David Song.

Most healthcare companies will benefit from the incentive the bill gives providers to give more care, Barron’s wrote.

For example, diagnostic-testing company Laboratory Corp of America LH.N may be priced conservatively, Barron's wrote.

Drugmakers Amgen AMGN.O, which has a new pill for osteoporosis, and Alexion Pharmaceuticals ALXN.O, which has an approved drug for a rare blood disorder, should both gain from certain provisions of the Senate bill dealing with marketing exclusivity, Barron's wrote, citing Song. (Reporting by Phil Wahba; Editing by Steve Orlofsky)